Vontobel Holding Ltd. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vontobel Holding Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 35.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,108 shares of the biopharmaceutical company's stock after selling 3,858 shares during the quarter. Vontobel Holding Ltd.'s holdings in Regeneron Pharmaceuticals were worth $6,243,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Sunbelt Securities Inc. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Sutton Wealth Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $40,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares of the company's stock, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last three months, insiders sold 13,729 shares of company stock valued at $13,124,641. Insiders own 8.83% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on REGN. Barclays increased their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a report on Tuesday, January 23rd. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an "outperform" rating and a $1,125.00 price objective for the company. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an "underperform" rating in a report on Friday, April 12th. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, April 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $970.57.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of Regeneron Pharmaceuticals stock traded up $7.05 during trading on Wednesday, hitting $901.19. 468,666 shares of the stock were exchanged, compared to its average volume of 495,554. The stock has a market cap of $98.91 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 2.62 and a beta of 0.11. The firm's 50-day moving average price is $955.19 and its 200 day moving average price is $890.52. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $10.96 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.